Press Releases

August 29, 2017

Ferring Pharmaceuticals to Donate $25,000 to Hurricane Harvey Relief

Ferring Pharmaceuticals announced today that it will donate $25,000 to help the people and communities impacted by Hurricane Harvey. Ferring will make its donation to the American Red Cross, which has mobilized its resources to respond to the devastation in Texas and across the Gulf Coast region. (more)

June 01, 2017

Paul Navarre Joins Ferring Pharmaceuticals as Chief Executive Officer of Ferring Holding Inc.

Ferring Pharmaceuticals announced today that Paul Navarre has been appointed Chief Executive Officer of Ferring Holding Inc. In this role Mr. Navarre assumes direct responsibility for all Ferring US activities including commercial operations, clinical development and manufacturing. He succeeds Aaron Graff, who has been appointed to a global role as Executive Vice President, Chief Commercial Officer and member of the Ferring Group Executive Board. (more)

June 01, 2017

Ferring appoints Aaron Graff to Executive Board

Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive Board, effective immediately. (more)

April 24, 2017

Ferring Pharmaceuticals Launches Two New Resources to Help Women Struggling with Infertility during National Infertility Awareness Week®

PARSIPPANY, NJ (April 24, 2017) – Infertility is no longer something that people feel they must discuss behind closed doors. Gone are the days of hushed voices and cover stories; now, hardly a day goes by without another celebrity couple sharing that they have frozen their eggs, are undergoing fertility treatment, or are struggling to conceive. (more)

November 14, 2016

FERRING PHARMACEUTICALS HIGHLIGHTS ONGOING SPONSORSHIP OF ARTHRITIS FOUNDATION THROUGH FUNDRAISING EVENTS

PARSIPPANY, N.J., Nov. 14, 2016 /PRNewswire/ -- Ferring Pharmaceuticals Inc. will continue its leadership role as one of four national sponsors for the more than 100 Arthritis Foundation Jingle Bell Run events taking place in cities across the country. Through this sponsorship, Ferring Pharmaceuticals will support the Arthritis Foundation's search for a cure to the number one cause of disability in the United States, while also providing life-changing tools, resources, and science and advocacy initiatives to help arthritis sufferers in their daily lives. (more)

April 25, 2016

Ferring Pharmaceuticals and National Style Expert Bobbie Thomas Launch the Fertility Facts: Know More. Start Asking. Campaign during National Infertility Awareness Week®

Have you ever heard people talk about how having a baby later in life is easy, so long as you’re healthy and in good shape? Or, that issues with fertility are usually the woman’s fault? These are just a few of the many myths about fertility and why Ferring Pharmaceuticals has launched Fertility Facts: Know More. Start Asking. This new campaign, created in collaboration with the American Society for Reproductive Medicine (ASRM) and RESOLVE: The National Infertility Association, encourages people to learn the important facts about fertility by establishing an open dialogue with a trusted physician on the topic. (more)

April 07, 2016

Couple’s Inspiring Video on Overcoming Infertility, Fighting Cancer Wins Educational Grant

Ferring Pharmaceuticals Inc. today announced Katie and Jake Barber of Waterford, Mich. as the winners of its annual Heart to Heart Video Contest. The Barber family received the highest number of votes in the contest's history. For more than a decade, the company has been providing parents who struggled with infertility the opportunity to win up to $10,000 toward their child's education by sharing their stories to encourage hope and positivity. (more)

March 01, 2016

Ferring names Aaron Graff as Chief Executive Officer of US Holding Company

PARSIPPANY, N.J., March 1, 2016 – Ferring Pharmaceuticals today announced that Aaron Graff has been appointed Chief Executive Officer of Ferring Holding Inc. In this role Mr. Graff assumes direct responsibility for all Ferring US activities including commercial operations (Ferring Pharmaceuticals Inc.), clinical development (Ferring International PharmaScience Center US), and manufacturing (Ferring Production Inc.). (more)

November 10, 2015

FERRING PHARMACEUTICALS NAMED AS NATIONAL SPONSOR OF ARTHRITIS FOUNDATION FUNDRAISING EVENTS

PARSIPPANY, NEW JERSEY [NOVEMBER 10, 2015] – Ferring Pharmaceuticals Inc. has agreed to take on a leadership role as one of three national sponsors for the more than 100 Arthritis Foundation Jingle Bell Run/Walk events taking place in cities across the country. Through this sponsorship, Ferring Pharmaceuticals will support the Arthritis Foundation’s search for a cure to the number one cause of disability in the United States, while also providing life-changing tools, resources, and science and advocacy initiatives to help arthritis sufferers in their daily lives. (more)

October 09, 2015

Ferring Research Institute Inc. Announces Recipients of Ferring Innovation Grants

SAN DIEGO–(BUSINESS WIRE)–Ferring Research Institute Inc. today announced the recipients of the 2015 Ferring Innovation Grants. “We are delighted with the response to the 2015 Ferring Innovation Grant initiative and look forward to the outcome of the innovative research being carried out by all of this year’s grant awardees” (more)

April 22, 2015

Inflammatory Bowel Disease Treatment Gets Boost From New Educational Resource

Saint-Prex, Switzerland / Amsterdam, The Netherlands, 22 April 2015 – A new educational resource for doctors and healthcare professionals will help improve knowledge and treatment of Inflammatory Bowel Disease (IBD). The Inflammatory Bowel Disease Resource Centre (www.IBD-RC.com) was developed by Elsevier, the journal Digestive and Liver Disease, and was made possible through an educational grant from Ferring Pharmaceuticals. The Inflammatory Bowel Disease is a free online platform designed to increase healthcare professionals’ knowledge of IBD (more)

April 20, 2015

Ferring Pharmaceuticals Launches 2015 Heart to Heart Video Contest Supporting Families Who’ve Overcome Infertility

PARSIPPANY, N.J., April 20, 2015 /PRNewswire-USNewswire/ -- Ferring Pharmaceuticals Inc. today announced the launch of its 2015 Heart to Heart Video Contest, coinciding with National Infertility Awareness Week (NIAW). Through the contest, Ferring strives to inspire hope for the millions of Americans affected by infertility, and raise awareness of the disease. (more)

March 31, 2015

Ferring Pharmaceuticals Receives FDA Approval for Growth Hormone Name Change, Acquires ZOMACTON™ [somatropin (rDNA origin)] for Injection and Needle-Free Device in the U.S.

PARSIPPANY, N.J., March 31, 2015 – Ferring Pharmaceuticals Inc. today announced U.S. Food and Drug Administration (FDA) approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as ZOMACTON™ [somatropin (rDNA origin)] for injection, and its needle-free delivery system to be marketed in the U.S. as ZOMA-Jet™. (more)

December 04, 2014

Ferring Pharmaceuticals Announces Grand Opening of U.S. Operations Center

Parsippany, NJ, USA, 4 December 2014 – Ferring Pharmaceuticals has expanded its footprint in New Jersey with the opening of its new U.S. Operations Center on a 25-acre lot located at 100 Interpace Parkway in Parsippany. Instead of relocating or outsourcing manufacturing to other states or overseas, Ferring’s new center is a sign of the company’s continued commitment to New Jersey and bringing new jobs to the local community. (more)

October 07, 2014

FERRING PHARMACEUTICALS INC. RECEIVES FDA APPROVAL FOR NEW CRANBERRY FLAVOR OF PREPOPIK® (SODIUM PICOSULFATE, MAGNESIUM OXIDE, AND ANHYDROUS CITRIC ACID)

PARSIPPANY, N.J., Oct. 7, 2014 /PRNewswire/ – Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself.  To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. The cranberry flavor of PREPOPIK was approved by the U.S. Food and Drug Administration (FDA) on August 22, 2014. (more)

March 19, 2014

FERRING PHARMACEUTICALS INC. RECEIVES FDA APPROVAL FOR THE FIRST AND ONLY MIXED PROTOCOL IVF TREATMENT — COMBINES MENOPUR® (MENOTROPINS FOR INJECTION) AND BRAVELLE® (UROFOLLITROPIN FOR INJECTION, PURIFIED) IN SINGLE SYRINGE

PARSIPPANY, NJ (March 19, 2014) – Ferring Pharmaceuticals Inc. today announced FDA approval of new labeling for their fertility products, MENOPUR and BRAVELLE. The label update is a result of the COMBINE trial which demonstrated that both MENOPUR and BRAVELLE can be safely mixed and administered in a single injection. Approval was granted on February 19, 2014 and designates Ferring’s mixed protocol as the only combination of IVF stimulation gonadotropins to have regulatory backing for being mixed together in a single syringe. (more)

June 03, 2013

FERRING PHARMACEUTICALS INC. ANNOUNCES $1M DONATION TO THE ALLIANCE FOR FERTILITY PRESERVATION, A NEWLY FORMED CHARITABLE ORGANIZATIONFERRING PHARMACEUTICALS INC. ANNOUNCES $1M DONATION TO THE ALLIANCE FOR FERTILITY PRESERVATION, A NEWLY FORMED CHARITABLE ORGANIZATION

PARSIPPANY, N.J., June 3, 2013 – Today, Ferring Pharmaceuticals Inc. announced that it will donate $1M to the Alliance for Fertility Preservation (the Alliance), a newly formed 501c3 charitable organization established by and comprised of experts representing a broad range of disciplines. The Alliance helps to promote the education of patients diagnosed with cancer to enable them to make the best informed decisions regarding fertility preservation options prior to commencement of treatment and to better understand potential opportunities to help manage infertility after treatment. (more)

May 02, 2013

FERRING ANNOUNCES IT WILL PRESENT PHASE 3 DATA FOR CERVICAL RIPENING AGENT AT AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS ANNUAL CLINICAL MEETING

NEW ORLEANS, LA. (May 2, 2013) – Ferring Pharmaceuticals will present efficacy and safety data from its Phase 3 EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 61st annual clinical meeting of the American College of Obstetricians and Gynecologists in New Orleans, May 4 – 8, 2013. (more)

February 12, 2013

FERRING TO HIGHLIGHT PHASE 3 DATA FOR CERVICAL RIPENING CANDIDATE AT SOCIETY FOR MATERNAL-FETAL MEDICINE ANNUAL MEETING

San Francisco, Calif. (February 12, 2013) – Ferring Pharmaceuticals will present pivotal Phase 3 efficacy and safety data from its EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 33rd annual meeting of the Society for Maternal-Fetal Medicine (SMFM) in San Francisco, February 11 - 16. These and other research findings formed the basis for Ferring’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) supporting the use of the controlled release MVI as a treatment option for cervical ripening as part of the labor induction process. (more)

October 23, 2012

FERRING ANNOUNCES FDA ACCEPTANCE OF NDA FILING FOR CONTROLLED RELEASE MISOPROSTOL VAGINAL INSERT FOR DECREASING TIME TO VAGINAL DELIVERY IN WOMEN

PARSIPPANY, NJ, October 23, 2012 – Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its controlled release misoprostol vaginal insert (MVI). Ferring is seeking approval for the MVI for decreasing time to vaginal delivery in women with an unfavorable cervix (a cervix that has not yet softened and thinned so that dilation can take place) when used in sequential regimen with oxytocin augmentation, if needed. (more)

September 20, 2012

NJBIZ HONORS NEW JERSEY’S 50 FASTEST GROWING COMPANIES

Ferring Pharmaceuticals Inc. has been named one of New Jersey’s 2012 50 Fastest Growing Companies. The award program produced by NJBIZ, New Jersey’s premiere business news publication, is presented by ParenteBeard and sponsored by PNC Bank and UnitedHealthcare. (more)

September 06, 2012

WALGREENS JOINS WITH FERRING PHARMACEUTICALS INC. TO OFFER PRODUCTS AND RESOURCES TO WOMEN FACING FERTILITY COMPLICATIONS FROM CANCER TREATMENT

DEERFIELD, Ill. and PARSIPPANY, N.J., Sept. 6, 2012– In honor of National Ovarian Cancer Month and Gynecologic Cancer Month, both taking place in September, Walgreens and Ferring Pharmaceuticals Inc. today announced a collaboration to provide free access to certain fertility medications and educational resources as part of Ferring’s h.e.a.r.t BEAT program. The program is a patient assistance initiative funded by Ferring and provided as a public service to eligible women of reproductive age who have received a new cancer diagnosis and wish to undergo fertility preservation prior to the start of their cancer treatment. (more)

July 17, 2012

FDA APPROVES FERRING’S PREPOPIK™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) FOR COLONOSCOPY PREP

Parsippany, NJ —July 17, 2012 —The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market PREPOPIK (sodium picosulfate, magnesium oxide, and anhydrous citric acid) for oral solution indicated for cleansing of the colon as a preparation for colonoscopy in adults. PREPOPIK is a low-volume, orange-flavored, dual-acting, stimulant and osmotic laxative. The FDA approval is based on data from two pivotal Phase III non-inferiority studies in which PREPOPIK was compared to 2L PEG+E plus 2x 5-mg bisacodyl tablets. In both studies, PREPOPIK achieved the primary endpoint (successful colon cleansing based on the Aronchick Scale), demonstrating non-inferiority to the comparator [Study 1: 84.2% v. 74.4%; Study 2: 83.0% v. 79.7%].1 Additionally, PREPOPIK demonstrated statistical superiority in cleansing of the colon versus the comparator.1 (more)

July 03, 2012

FERRING PHARMACEUTICALS ACQUIRES LICENSING RIGHTS FOR ELOBIXIBAT FROM ALBIREO AB

Saint-Prex, Switzerland, Gothenburg, Sweden, July 3, 2012 - Ferring Pharmaceuticals (Ferring) and Albireo AB (Albireo) announced today that they have signed a license agreement under which Ferring has rights to develop and commercialise elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). The agreement gives Ferring rights to market the product globally with the exception of Japan and a small number of Asian markets. In consideration of the rights, Ferring will pay Albireo a significant upfront licensing fee, milestones and tiered double-digit royalties. Ferring will also be responsible for development costs in its territory. (more)

December 09, 2011

EXPERTS LAUNCH THE ALLIANCE FOR FERTILITY PRESERVATION AT THE INTERNATIONAL SOCIETY FOR FERTILITY PRESERVATION’S 2ND WORLD CONGRESS

Miami Beach, FL Dec. 9, 2011 – As hundreds of scientists gathered today to discuss fertility preservation at the International Society for Fertility Preservation’s 2nd World Congress in Miami Beach, Fla., American experts in reproductive endocrinology, urology and oncology announced the formation of the Alliance for Fertility Preservation, a coalition to help newly diagnosed cancer patients in the United States access information about fertility preservation options. (more)

October 21, 2011

FERRING PHARMACEUTICALS TO DEVELOP MAJOR CORPORATE CENTER IN PARSIPPANY, NEW JERSEY

Parsippany, NJ —Oct. 21, 2011 — /PRNewswire/ – Switzerland-based Ferring Pharmaceuticals today announced the purchase of a 25-acre site at 100 Interpace Parkway in Parsippany, N.J. The new facility will house a state-of-the art, expanded U.S. Operations Center. The expansion is expected to generate jobs in the New Jersey area, countering recent trends in the pharmaceutical industry. The U.S. Operations Center will be a fully integrated pharmaceutical facility that will house management, administration and support, commercial operations, manufacturing and product development. It will include a state-of-the-art manufacturing suite, next-generation product development laboratories, a fully equipped education and training conference center, and administrative offices. “As a private company, Ferring has a long term orientation, as well as a commitment to follow the science to benefit patients. This new facility underscores our long-term commitment to the U.S. market, as well as the State of New Jersey,” said Aaron Graff, President and Chief Operating Officer of Ferring Pharmaceuticals, Inc. (more)

October 21, 2011

FDA APPROVES LONGER DURATION EFFICACY AND SAFETY FOR EUFLEXXA®

Parsippany, NJ —Oct. 21, 2011 — On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles. (more)

October 20, 2011

FERRING ACQUIRES CYTOKINE PHARMASCIENCES INC.

10/20/2011 - Ferring has completed the purchase of Cytokine PharmaSciences Inc. (CPSI) and its UK subsidiary Controlled Therapeutics (Scotland) Ltd. (CTS), a global biopharmaceutical company with a particular focus in obstetrics. (more)

October 17, 2011

RETROSPECTIVE ANALYSIS EVALUATES THE EFFECT OF LYSTEDA® ON THE NUMBER OF SLEEP INTERRUPTIONS FOR WOMEN WITH CYCLIC HEAVY MENSTRUAL BLEEDING

AUSTIN, TX – October 17, 2011 – According to a recent combined retrospective analysis of women with cyclic heavy menstrual bleeding*, LYSTEDA® (tranexamic acid) tablets significantly reduced the number of sleep interruptions during the night compared with placebo (-2.61 vs -1.81, respectively). The study results were presented at the Nurse Practitioners in Women’s Health 14th Annual Premier Women’s HealthCare Conference in Austin, TX, October 12-15, 2011. LYSTEDA is the only non-hormonal prescription medicine FDA-approved specifically to treat cyclic heavy menstrual bleeding. (more)

May 16, 2011

EXPLORATORY EFFICACY ANALYSIS CONDUCTED FOR LONG-TERM EXTENSION STUDY IN PATIENTS WITH PROSTATE CANCER TREATED WITH FIRMAGON® OR CROSSED OVER TO FIRMAGON FROM LEUPROLIDE

WASHINGTON, DC – May 16, 2011 – A poster entitled, “Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment,” is being presented at the American Urological Association 2011 meeting by E. David Crawford, MD, head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center in Denver, and lead study investigator. The full manuscript has just been accepted and will be published in the September 2011 issue of the Journal of Urology. Other investigators for the study, sponsored by Ferring Pharmaceuticals Inc., included J.W. Moul, N. Shore, E. van der Meulen, and B.E. Persson. (more)

May 06, 2011

FERRING PHARMACEUTICALS TO SUPPORT GREAT PROSTATE CANCER CHALLENGE® EVENTS ACROSS THE COUNTRY IN NATIONAL EFFORT TO END PROSTATE CANCER

PARSIPPANY, NJ – May 6, 2011 – Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), a hormone antagonist therapy for advanced prostate cancer, has joined the race to end prostate cancer as an official sponsor of the Great Prostate Cancer Challenge®, the fastest growing men’s health event series in the United States. Now in its fifth year, the Great Prostate Cancer Challenge (GPCC) is led by ZERO – The Project to End Prostate Cancer. (more)

May 04, 2011

RETROSPECTIVE ANALYSIS EXPLORES LYSTEDA®’S ABILITY TO REDUCE SLEEP INTERRUPTIONS IN WOMEN WITH CYCLIC HEAVY MENSTRUAL BLEEDING

Washington, DC – May 4, 2011 – Cyclic heavy menstrual bleeding (HMB) has been reported to significantly impact a woman’s ability to get uninterrupted sleep which can often lead to daytime fatigue and irritability.1 According to a recent retrospective analysis of the 6-cycle pivotal trial that supported product approval, women taking LYSTEDA® (tranexamic acid) Tablets, 3.9 g/day, experienced a 0.99 mean reduction in the number of sleep interruptions over baseline (1.65) compared with a 0.70 mean reduction over baseline (1.92) for women in the placebo group (P=.0024). LYSTEDA is a non-hormonal and non-surgical therapy specifically indicated for women with heavy menstrual bleeding that is taken only during menstruation. (more)

April 25, 2011

FERRING CELEBRATES WINNERS OF 2010 MY LITTLE MIRACLE ESSAY CONTEST DURING NATIONAL INFERTILITY AWARENESS WEEK

PARSIPPANY, NJ – April 25, 2011 – Celebrating National Infertility Awareness Week, April 24-30, 2011, Ferring Pharmaceuticals Inc. is honoring three lucky families who won its 2010 My Little Miracle Essay Contest for their inspirational stories about overcoming their struggle with infertility during their journey to parenthood. The contest celebrates the birth of children who were conceived using Ferring’s prescription products, MENOPUR® (menotropins for injection, USP) and/or BRAVELLE® (urofollitropin for injection, purified). The grand prize winner, Jennifer Adams Buckhouse of Colorado Springs, CO, received a $10,000 education fund, the second-place contest winner, Deena Kobell of Philadelphia, received an education fund of $7,500 and the third-place winner, Kristin Bedinghaus of St. Petersburg, FL, won a $5,000 education fund. (more)

March 21, 2011

NATIONAL SURVEY OF NURSE PRACTITIONERS REVEALS SERIOUS TOLL OF HEAVY MONTHLY PERIODS

Washington, DC – March 21, 2011 – Millions of American women suffer from cyclic heavy menstrual bleeding (HMB), and a recent national survey of more than 1,600 nurse practitioners revealed that this condition has a considerable negative impact on patients’ health, lifestyle and even employment. Yet very few patients report their symptoms or request professional help, or they delay reporting their HMB to a medical professional from five months to more than one year, according to 82 percent of nurses. (more)

November 11, 2010

ZERO’S GREAT PROSTATE CANCER CHALLENGE COMES TO CENTRAL FLORIDA TO HELP STOP PROSTATE CANCER IN ITS TRACKS WITH HELP FROM FERRING PHARMACEUTICALS

PARSIPPANY, NJ – November 11, 2010 – Men, women and children from Central Florida have a chance to help stop prostate cancer in its tracks. The Great Prostate Cancer Challenge (GPCC) / Dash for Dad, led by ZERO – The Project to End Prostate Cancer, together with its official sponsor Ferring Pharmaceuticals Inc., the makers of FIRMAGON®(degarelix for injection—a hormone antagonist therapy for advanced prostate cancer), will take place adjacent to The Villages on Saturday, November 20, 2010. Members of the community are encouraged to lace up their sneakers for this important cause, or sponsor those who participate. The 5K Run/Walk begins at 8:00 AM in Oxford, FL at the Central Florida Prostate Cancer Center. All participants will receive a long sleeve performance shirt and “goodie bag” of products from area businesses. Awards will be presented to men and women in different age groups. (more)

November 01, 2010

ZERO’S DASH FOR DAD AIMS TO STOP PROSTATE CANCER IN ITS TRACKS WITH HELP FROM FERRING PHARMACEUTICALS

PARSIPPANY, NJ – November 1, 2010 – Men, women and children from Long Island and beyond have a chance to help stop prostate cancer in its tracks. The Great Prostate Cancer Challenge (GPCC) / Dash for Dad, led by ZERO — The Project to End Prostate Cancer, together with its official sponsor Ferring Pharmaceuticals Inc., the makers of FIRMAGON®(degarelix for injection—a hormone antagonist therapy for advanced prostate cancer), will take place on Sunday, November 14, 2010. New Yorkers are encouraged to lace up their sneakers for this important cause, or sponsor those who participate. The start time for the half mile “Fun Walk,” which is open to people of all ages, is 8:20 AM. The 5K run begins at 9:00 AM. Walkers and runners will meet at the Town of Oyster Bay Golf Course, where free prostate cancer screenings will be available from 7:30 AM to 11:00 AM. Every entrant will receive a commemorative sweatshirt. (more)

October 26, 2010

ENDOMETRIN VAGINAL INSERTS DEMONSTRATE COMPARABLE EFFICACY TO INTRAMUSCULAR INJECTIONS OF PROGESTERONE-IN-OIL FOR LUTEAL SUPPORT IN GNRH IVF CYCLES

DENVER – October 26, 2010 – Ferring Pharmaceuticals Inc. presented study results demonstrating that ENDOMETRIN® (progesterone) Vaginal Insert provides effective luteal support compared to intramuscular (IM) progesterone-in-oil (PIO) in patients undergoing in vitro fertilization (IVF) using gonadotropin releasing hormone (GnRH) antagonist. The results were presented at the 66th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Denver, October 23 - 27, 2010. (more)

October 06, 2010

OBSTETRICS AND GYNECOLOGY PUBLISHES DATA FROM PIVOTAL PHASE 3 LYSTEDA STUDY

Parsippany, NJ – October 6, 2010 – Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA™ (tranexamic acid) tablets for cyclic heavy menstrual bleeding (HMB) in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability. It is estimated that up to 22 million women suffer from HMB in the U.S.1,2 (more)

September 29, 2010

GLORIA GAYNOR TO APPEAR AT AARP’s ORLANDO@50+ NATIONAL EVENT & EXPO

Parsippany, NJ- September 29, 2010 – Grammy Award winner Gloria Gaynor—whose hit songs have captivated the public for over 35 years—will appear at AARP’S Orlando@50+ National Event & Expo to raise awareness of knee osteoarthritis (OA), including her own experience with this potentially debilitating condition. This high profile event, with an estimated attendance of 25,000, will take place September 30-October 2 at the Orange County Convention Center in Orlando, FL. (more)

September 23, 2010

“THE QUEEN OF DISCO” GLORIA GAYNOR TO PERFORM AT HUNTSMAN WORLD SENIOR GAMES

Parsippany, NJ – September 23, 2010 – Disco icon Gloria Gaynor, whose career spans three decades and includes the Grammy award winning anthem, “I Will Survive,” will be the headline performer for the opening ceremonies of the Huntsman World Senior Games on October 5th to raise awareness of knee osteoarthritis(OA), including her own experience with the pain of this potentially debilitating condition. The Huntsman World Senior Games is an international sports competition scheduled for October 4-16 in St. George, Utah. More than 10,000 athletes will participate in this year’s Games, the highest number in the event’s history. As the national spokesperson for EUFLEXXA® (1% sodium hyaluronate), a treatment for the pain of knee osteoarthritis, Ms. Gaynor is bringing attention to the prevalence of knee osteoarthritis, and the medical options available to treat the pain it causes. (more)

September 14, 2010

LANDMARK NATIONAL SURVEY CONDUCTED BY HARRIS INTERACTIVE® SHEDS LIGHT ON HIDDEN PROBLEM OF HEAVY MONTHLY PERIODS

Parsippany, NJ – September 14, 2010 – Nearly ninety percent of women who experience heavy periods1 believe their life during their period would greatly improve if they could reduce their menstrual flow, according to a new Harris Interactive® survey commissioned by Ferring Pharmaceuticals. Living With HMB: A National Survey of 500 Women found that many women experience monthly periods that are so heavy they can sap energy, cause anemia, and in many ways interfere with daily activities. However, many women accept a heavy period as normal or are embarrassed to discuss it, and may be unaware that there are new treatment options available that can help provide substantial relief. (more)

August 16, 2010

FERRING PHARMACEUTICALS’ FIRMAGON® JOINS RACE TO END PROSTATE CANCER AS OFFICIAL SPONSOR OF THE GREAT PROSTATE CANCER CHALLENGE / DASH FOR DAD

PARSIPPANY, NJ – August 16, 2010 – Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), is in the race to end prostate cancer as an official sponsor of the Great Prostate Cancer Challenge / Dash for Dad, the premier prostate cancer race series in the United States, led by ZERO – The Project to End Prostate Cancer. FIRMAGON® is a hormone antagonist therapy for advanced prostate cancer. (more)

July 12, 2010

FERRING PHARMACEUTICALS’ FIRMAGON® NAMED OFFICIAL SPONSOR OF ED RANDALL’S BAT FOR THE CURE

PARSIPPANY, NJ – July 12, 2010 – Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), will sponsor Ed Randall’s Bat for the Cure charity, in an effort to “strike-out prostate cancer” with awareness, education, effective management and prevention support at the organization’s Minor League Baseball initiative across the country. FIRMAGON® is a hormone antagonist therapy for advanced prostate cancer. (more)

June 21, 2010

Ferring Pharmaceuticals Announces Immediate Availability Of Lysteda™, The First Non-Hormonal Therapy Indicated Specifically For Cyclic Heavy Menstrual Bleeding

Parsippany, NJ – June 21, 2010 – Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use. It also significantly reduced limitations on social, leisure and physical activities in women with cyclic HMB. It is estimated that up to 22 million women suffer from HMB in the U.S.1,2 (more)

June 01, 2010

Extension study with FIRMAGON® (degarelix) showed continued benefits for prostate cancer patients beyond one year

San Francisco, CA – June 1, 2010 – Prostate cancer patients on leuprolide who were offered to continue on FIRMAGON® (degarelix for injection) after one year of treatment reduced prostate specific antigen (PSA) recurrence, according to results of a Phase III extension study,1 presented here at the American Urological Association 2010 meeting. PSA is commonly used in monitoring prostate cancer patients’ treatment response, and a high PSA number may indicate prostate cancer presence or recurrence. (more)

June 01, 2010

FIRMAGON® RESULTS IN FAST, LONG-TERM SUPPRESSION OF TESTOSTERONE IN PROSTATE CANCER PATIENTS WITHOUT INITIAL TESTOSTERONE SURGE

SAN FRANCISCO – June 1, 2010 – FIRMAGON® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr. Judd Moul, Chief of the Division of Urology at Duke University Health Science Center. (more)

May 19, 2010

CLINICAL DATA DEMONSTRATES THAT LYSTEDA™ SIGNIFICANTLY REDUCED MENSTRUAL BLOOD LOSS AND LIMITATIONS ON SOCIAL, LEISURE AND PHYSICAL ACTIVITIES IN WOMEN WITH CYCLIC HMB

San Francisco - May 19, 2010 - Five presentations reporting the results of two placebo-controlled clinical trials evaluating Ferring Pharmaceuticals’ LYSTEDA™ (tranexamic acid) tablets, a novel, first-in-class, non-hormonal therapy indicated for treatment of women with cyclic heavy menstrual bleeding (HMB), were presented at The American College of Obstetricians and Gynecologists 58th Annual Clinical Meeting in San Francisco, May 15-19, 2010. It is estimated that up to 22 million women suffer from HMB in the U.S.1,2 (more)

May 17, 2010

GLORIA GAYNOR TO PERFORM AT JACKSONVILLE’S SENIOR EXPO AND HEALTH FAIR

Parsippany, NJ – Grammy Award winner Gloria Gaynor—whose hit songs have captivated the public for over 35 years—will perform at the City of Jacksonville’s 14th Annual Senior Expo and Health Fair at the Prime Osborn Convention Center on May 19, 2010 to raise awareness of knee osteoarthritis (OA). (more)

May 12, 2010

FERRING PHARMACEUTICALS ANNOUNCES DISCO ICON GLORIA GAYNOR AS NATIONAL SPOKESPERSON FOR EUFLEXXA®

Parsippany, NJ – Ferring Pharmaceuticals Inc. announces that Grammy Award winner Gloria Gaynor will serve as the national spokesperson for the company’s hyaluronic acid treatment therapy, EUFLEXXA® (1% sodium hyaluronate), for the pain associated with knee osteoarthritis (OA). The announcement comes as Gaynor celebrates the 30th anniversary of her number one hit single, “I Will Survive.” Gaynor has been nicknamed the “Queen of Disco” and her songs and iconic voice define a generation. (more)

May 10, 2010

FERRING ACQUIRES LYSTEDA™ FROM XANODYNE PHARMACEUTICALS, INC.

SAINT-PREX, Switzerland – May 10, 2010 – Ferring Pharmaceuticals today announced an agreement that will expand its Women’s Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical’s LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB). The company will initially market LYSTEDA in the U.S., and is evaluating opportunities in other markets. LYSTEDA oral tablets received approval on November 13, 2009 following a Priority Review by the U.S. Food and Drug Administration (FDA). It is estimated that up to 22 million women suffer from HMB in the U.S.1,2 (more)

April 01, 2010

XANODYNE AND FERRING ANNOUNCE CO-PROMOTE FOR ZIPSOR™

NEWPORT, Ky. and PARSIPPANY, N.J., April 1 /PRNewswire/ – Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management, today announced that it has signed a co-promotion agreement for Zipsor™ (diclofenac potassium) Liquid Filled Capsules with Ferring Pharmaceuticals Inc., a global bio-pharmaceutical company, headquartered in Switzerland. Zipsor, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain in adults received FDA approval in June 2009, and diclofenac, the active ingredient in Zipsor, is one of the most widely prescribed NSAIDs in the world. (more)

March 08, 2010

NEW ARTICLE REVEALS TREND TOWARD GREATER USE OF HUMAN MENOPAUSAL GONADOTROPIN IN IN VITRO FERTILIZATION

PARSIPPANY, NJ – March 8, 2010 – The U.S. infertility specialty has empirically incorporated greater amounts of human menopausal gonadotropin (hMG) into stimulation protocols, according to a new review article, “Gonadotropins in the Treatment of Infertility” by George T. Koulianos, MD, published in a recent issue of US Obstetrics & Gynecology, supported by an educational grant from Ferring Pharmaceuticals.1 The article reviews the wealth of clinical evidence supporting this trend, and demonstrates how the use of gonadotropins in the treatment of infertility, especially in assisted reproductive technologies, has significantly improved outcomes. (more)

March 01, 2010

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

PARSIPPANY, NJ – March 1, 2010 - If you are a parent who has conceived using Ferring Pharmaceuticals’ fertility products, you can win a $10,000 education fund to support your child’s future. Two other education fund prizes will also be awarded. To be eligible, all you need to do is write a brief essay. The topic is: If I Knew Then What I Know Now, explaining what advice you would give to other women who are coping with infertility and how you would describe your success using BRAVELLE® (urofollitropin for injection, purified) and/or MENOPUR® (menotropins for injection, USP) as part of your treatment plan. (more)

February 25, 2010

FERRING PHARMACEUTICALS AND GENE SECURITY NETWORK PARTNER TO TEST ADVANCED PREIMPLANTATION GENETIC DIAGNOSIS (PGD) TECHNOLOGY

PARSIPPANY, NJ and REDWOOD CITY, CA – February 25, 2010 – Ferring Pharmaceuticals and Gene Security Network (GSN) announced that they have signed an agreement to conduct a clinical trial of GSN’s advanced preimplantation genetic diagnosis (PGD) technology, Parental Support™. The 11-center U.S. trial is designed to evaluate if GSN’s PGD technology helps increase in vitro fertilization (IVF) success rates when using single cell embryo testing for an abnormal number of chromosomes, a condition called aneuploidy. GSN’s Parental Support technology is designed to help improve embryo selection during IVF procedures in order to increase the pregnancy rate following embryo transfer compared with IVF procedures without embryo PGD testing. (more)

view our full press archives
This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience.

©2008-2019 Ferring Pharmaceuticals.  US--1900006